Given the growing number of long-term survivors of EGFR-mutated lung cancer due to advances in targeted therapy, clinicians should be aware that very late recurrences can occur through atypical metastatic routes such as tumor-to-tumor metastasis. Here, EGFR is linked to lung cancer.